Asahi Intecc $7747 (+0,25%) is a leading manufacturer of high-precision guidewires, catheters and related products for minimally invasive procedures, particularly in cardiology (e.g. PTCA). The company operates internationally, with a strong focus on technological innovation and micro-precision manufacturing. Its main markets are Japan, the USA, Europe and Asia.
📊 Key financial figures (FY 2024, as at March 2025):
- Sales: ¥75.2 billion (~€480 million)
- Operating profit: ¥20.5 billion (~€131 million)
- Net profit: ¥15.3 billion (~€98 million)
- Profit margin: approx. 20.3%
- EPS (earnings per share): ¥127,6
- Dividend: ¥18 per share
- Equity ratio: approx. 80%
- Market capitalization: approx. ¥450 billion (~€2.9 billion)
➡️ Stable growth with strong margins and continuous product innovation.
🚀 Strengths & opportunities:
- Technology leadership in micro-precision guidewires
- High R&D investments (~10% of sales)
- Strong balance sheet, hardly any debt
- Global megatrend: minimally invasive procedures
- Expansion into growth markets (Asia, USA) and new areas (neuro, peripheral)
⚠️ Risks:
- Competition (e.g. Boston Scientific, Terumo)
- Dependence on regulatory approvals (e.g. FDA, CE)
- Currency risks (export focus)
- Dependence on a few product categories
💡 Conclusion:
Asahi Intecc is a fast-growing Japanese medtech specialist with a solid balance sheet, high profitability and a clear niche strategy. An exciting small/mid-cap with global potential for long-term investors in the medical technology sector.
